Despite the heterogeneity of neuroblastoma metabolism in general, there appears to be a specific pattern in high-risk, MYCN-amplified disease involving a metabolic transformation favouring fatty acid uptake and mitochondrial respiration and preferential utilisation of glutamine and cysteine for cell survival, that altogether uncover novel opportunities for targeted therapeutics. The gene discussed is MYCN; the disease is neuroblastoma.